These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7000857)

  • 21. Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitin sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions.
    Bosso JA; Townsend RJ
    Am J Hosp Pharm; 1985 Oct; 42(10):2211-4. PubMed ID: 3864367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability of frozen solutions of cefamandole nafate.
    Bornstein M; Klink PR; Farrell BT; Winely CL; Boylan JC
    Am J Hosp Pharm; 1980 Jan; 37(1):98-101. PubMed ID: 7361780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents.
    Hayward CJ; Nafziger AN; Kohlhepp SJ; Bertino JS
    Antimicrob Agents Chemother; 1996 Feb; 40(2):485-7. PubMed ID: 8834905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics of cefamandole in rabbits].
    Klimova VS; Bobrov VI; Nazarova OI; Skala LZ; Iakovlev VP
    Antibiotiki; 1982 Dec; 27(12):34-8. PubMed ID: 7165292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds.
    Neu HC
    J Infect Dis; 1978 May; 137 Suppl():S80-S87. PubMed ID: 650006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cefamandole nafate in short-term prophylaxis in obstetric and gynecologic surgery].
    Accardo FM; Mancuso A; Granese D; Dugo C
    Minerva Ginecol; 1983 May; 35(5):351-6. PubMed ID: 6877656
    [No Abstract]   [Full Text] [Related]  

  • 27. Bioavailability in human volunteers of three intramuscular formulations of cefonicid: a long-acting cephalosporin.
    Brumfitt W; James I; Hamilton-Miller JM; Grady D; Price C
    Biopharm Drug Dispos; 1988; 9(3):251-7. PubMed ID: 3395666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical application of lidocaine-prilocaine (EMLA) cream reduces the pain of intramuscular infiltration of saline solution.
    Himelstein BP; Cnaan A; Blackall CS; Zhao H; Cavalieri G; Cohen DE
    J Pediatr; 1996 Nov; 129(5):718-21. PubMed ID: 8917239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of irrigation or intravenous antibiotic prophylaxis on infectious morbidity at cesarean section.
    Gonen R; Samberg I; Levinski R; Levitan Z; Sharf M
    Obstet Gynecol; 1986 Apr; 67(4):545-8. PubMed ID: 3960427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefamandole nafate therapy in the treatment of acute urinary tract infections.
    Short HD; Gentry LO; Sessoms S
    J Antimicrob Chemother; 1976 Dec; 2(4):345-50. PubMed ID: 802125
    [No Abstract]   [Full Text] [Related]  

  • 31. A review of the pharmacology of cefamandole.
    Neu HC
    Scand J Infect Dis Suppl; 1980; suppl 25():39-44. PubMed ID: 6937950
    [No Abstract]   [Full Text] [Related]  

  • 32. Lidocaine as a diluent for administration of benzathine penicillin G.
    Amir J; Ginat S; Cohen YH; Marcus TE; Keller N; Varsano I
    Pediatr Infect Dis J; 1998 Oct; 17(10):890-3. PubMed ID: 9802630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formylation of glucose by cefamandole nafate at alkaline pH.
    Indelicato JM; Stewart BA; Engel GL
    J Pharm Sci; 1980 Oct; 69(10):1183-8. PubMed ID: 7420288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of cefamandole nafate injection with parenteral solutions and additives.
    Frable RA; Klink PR; Engel GL; Mundell EE
    Am J Hosp Pharm; 1982 Apr; 39(4):622-7. PubMed ID: 7082453
    [No Abstract]   [Full Text] [Related]  

  • 35. Lidocaine as a diluent for ceftriaxone in the treatment of gonorrhea. Does it reduce the pain of the injection?
    Schichor A; Bernstein B; Weinerman H; Fitzgerald J; Yordan E; Schechter N
    Arch Pediatr Adolesc Med; 1994 Jan; 148(1):72-5. PubMed ID: 8143016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pain intensity and bioavailability of intramuscular asparaginase and a local anesthetic: a double-blinded study.
    Albertsen BK; Hasle H; Clausen N; Schrøder H; Jakobsen P
    Pediatr Blood Cancer; 2005 Mar; 44(3):255-8. PubMed ID: 15503298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of cefamandole nafate and cefoxitin sodium solutions.
    Das Gupta V; Stewart KR
    Am J Hosp Pharm; 1981 Jun; 38(6):875-9. PubMed ID: 7246563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis.
    Ahern MJ; Finkelstein FO; Andriole VT
    Antimicrob Agents Chemother; 1976 Sep; 10(3):457-61. PubMed ID: 984787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous determination of cefamandole and cefamandole nafate in human plasma and urine by high-performance liquid chromatography with column switching.
    Lee HS; Zee OP; Kwon KI
    J Chromatogr; 1990 Jun; 528(2):425-33. PubMed ID: 2384580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceforanide kinetics.
    Estey EH; Weaver SS; LeBlanc BM; Brown N; Ho DH; Bodey GP
    Clin Pharmacol Ther; 1981 Sep; 30(3):396-403. PubMed ID: 7273604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.